fda approval of tirzepatide for weight loss Day 4: Zepbound (Tirzepatide – indication) Approved: November 2023 weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management GROUNDBREAKING UPDATE! FDA has approved

Please talk with your pharmacy directly about insurance coverage

Some -- like insulin and GLP-1s -- are FDA-approved medicines that have been rigorously tested

All other authors declare no noteworthy conflicts of interest

Reddys Laboratories focusing on complex generics and GLP-1 opportunities Zydus Lifesciences advancing peptide-based and metabolic treatments Cipla exploring chronic therapy expansion Lupin Limited investing in diabetes-focused portfolios This shift is already driving meaningful change: Improved affordability Increased accessibility Greater patient awareness At the same time, it raises important concerns: Risk of off-label use for cosmetic weight loss Need for stronger regulatory oversight Importance of patient education and adherence As a pharmacy student, I may be wrong, but from my understanding, this is more than just a market trend It reflects how innovation, affordability, and regulation must evolve together to shape responsible healthcare

18 (download XLSX All source data in single file with clearly named tabs for Extended Data Figs

But you have to be realistic